RxDoctor Payments Data

Katelyn Maglione

Nurse Practitioner · Morristown, NJNPI 1053855502

Payments from drug & device makers

$4,660in general payments, 2019–2025

Across 207 payments — averaging $22.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AOP Health US, LLC$722
  • Abbott$639
  • Actelion Pharmaceuticals US, Inc.$543
  • Boehringer Ingelheim$389
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$365
  • Alnylam Pharmaceuticals Inc.$292
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$4,660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,660 in reported general payments places this provider in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$30,474
Medicare patients
107
Services billed
267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis85$2,098,611
EntrestoSacubitril/Valsartan101$110,422
FarxigaDapagliflozin Propanediol69$58,829
JardianceEmpagliflozin27$23,462
LokelmaSodium Zirconium Cyclosilicate21$7,273
Valsartan42$1,321
Eplerenone12$1,279
Torsemide43$894
Spironolactone75$656
Metoprolol Succinate41$361
Pregabalin12$353
Losartan Potassium23$346
Amlodipine Besylate17$178
Carvedilol35$175
Metoprolol Tartrate11$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax$248$2,098,61185 claims
NovartisEntresto$185$110,422101 claims
AstraZenecaFarxiga, Lokelma$232$66,10290 claims
Boehringer IngelheimJardiance$389$23,46227 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →